Compare · CI vs MDXH
CI vs MDXH
Side-by-side comparison of The Cigna Group (CI) and MDxHealth SA (MDXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and MDXH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $75.11B, about 3509.3x MDXH ($21.4M).
- Over the past year, CI is down 3.6% and MDXH is down 83.0% - CI leads by 79.4 points.
- CI has been more active in the news (7 items in the past 4 weeks vs 4 for MDXH).
- CI has more recent analyst coverage (25 ratings vs 5 for MDXH).
- Company
- The Cigna Group
- MDxHealth SA
- Price
- $283.93+0.88%
- $0.42-1.51%
- Market cap
- $75.11B
- $21.4M
- 1M return
- -0.43%
- -25.48%
- 1Y return
- -3.63%
- -83.03%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 5
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest CI
- New insider Holgerson Bryan claimed ownership of 7,693 shares (SEC Form 3)
- New insider Kautzner Adam claimed ownership of 13,533 shares (SEC Form 3)
- New insider Sadler Jason D claimed ownership of 34,705 shares (SEC Form 3)
- New insider Sanford Paul A claimed ownership of 4,073 shares (SEC Form 3)
- New insider Perlberg Matthew claimed ownership of 9,345 shares (SEC Form 3)
- The Cigna Group's Second Quarter 2026 Earnings Release Details
- Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
- The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities
- SEC Form 11-K filed by The Cigna Group
- The Cigna Group Foundation Invests $3 Million to Strengthen Youth Mental Health Through Nonprofits Across 10 States
Latest MDXH
- Amendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SA
- SEC Form 6-K filed by MDxHealth SA
- Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
- SEC Form 4 filed by Officer Sollee Joseph
- SEC Form 4 filed by Director Hardison Don M
- SEC Form 4 filed by Chief Executive Officer Mcgarrity Michael
- SEC Form 4 filed by VP, Finance and Accounting Oconnell Brendan
- SEC Form 4 filed by Director Hoffman Koen
- SEC Form 4 filed by Chief Commercial Officer Bellano John